Helmut Thomas
Chief Executive Officer at Cyclenium Pharma, Inc.
Profile
Helmut Thomas is the President, CEO & Chief Scientific Officer at Cyclenium Pharma, Inc. He previously worked as an Executive Director at Novartis Pharma NV and as a Principal at Ciba-Geigy Corp.
He also served as the Senior VP-Research & Preclinical Development at Ocera Therapeutics, Inc. from 2011 to 2013 and as the Vice President-Drug Development at LymphoSign, Inc. from 2004 to 2009.
Dr. Thomas earned a doctorate degree from the University of Hannover in 1984.
Helmut Thomas active positions
| Companies | Position | Start |
|---|---|---|
Cyclenium Pharma, Inc.
 Cyclenium Pharma, Inc. Pharmaceuticals: MajorHealth Technology Cyclenium Pharma, Inc. is a privately held pharmaceutical research and development company based in Montréal, Canada. The Canadian company is focused on creating value through the progression of internal programs in oncology, infectious diseases, and inflammation/pain. Cyclenium is also providing its extensive experience and exploring its CMRT-based Quest™ screening library in risk-sharing partnerships with leading academic and research-driven non-profit organizations, as well as collaborations with innovative pharmaceutical and biotechnology companies worldwide seeking to modulate unique and difficult disease targets in diverse therapeutic areas. The company was founded by Mark L. Peterson, and the CEO is Helmut Thomas. | Chief Executive Officer | - |
Former positions of Helmut Thomas
| Companies | Position | End |
|---|---|---|
| OCERA THERAPEUTICS INC | Chief Tech/Sci/R&D Officer | - |
Novartis Pharma NV
 Novartis Pharma NV Pharmaceuticals: MajorHealth Technology Founded in 1996, Novartis Pharma NV is a Belgian pharmaceutical company that develops medicines. The private company is based in Brussels, Belgium and is a subsidiary of Novartis AG. | Director/Board Member | - |
| Ciba-Geigy Corp. | Corporate Officer/Principal | - |
LymphoSign, Inc.
 LymphoSign, Inc. BiotechnologyHealth Technology LymphoSign, Inc. develops drugs for the cancer treatment. It also develops drugs acting on signaling pathways involved in the progression of acute leukemias, lymphomas and solid tumors. The company was founded by Chaim Roifman in 2000 and is headquartered in Markham, Canada. | Chief Tech/Sci/R&D Officer | - |
Training of Helmut Thomas
| University of Hannover | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 5 |
|---|---|
| Ciba-Geigy Corp. | Health Technology |
Ocera Therapeutics, Inc.
 Ocera Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ocera Therapeutics, Inc. manufactures pharmaceuticals products. The company was founded in 2004 and is headquartered in Hazelwood, MO. | Health Technology |
LymphoSign, Inc.
LymphoSign, Inc. BiotechnologyHealth Technology LymphoSign, Inc. develops drugs for the cancer treatment. It also develops drugs acting on signaling pathways involved in the progression of acute leukemias, lymphomas and solid tumors. The company was founded by Chaim Roifman in 2000 and is headquartered in Markham, Canada. | Health Technology |
Novartis Pharma NV
Novartis Pharma NV Pharmaceuticals: MajorHealth Technology Founded in 1996, Novartis Pharma NV is a Belgian pharmaceutical company that develops medicines. The private company is based in Brussels, Belgium and is a subsidiary of Novartis AG. | Health Technology |
Cyclenium Pharma, Inc.
Cyclenium Pharma, Inc. Pharmaceuticals: MajorHealth Technology Cyclenium Pharma, Inc. is a privately held pharmaceutical research and development company based in Montréal, Canada. The Canadian company is focused on creating value through the progression of internal programs in oncology, infectious diseases, and inflammation/pain. Cyclenium is also providing its extensive experience and exploring its CMRT-based Quest™ screening library in risk-sharing partnerships with leading academic and research-driven non-profit organizations, as well as collaborations with innovative pharmaceutical and biotechnology companies worldwide seeking to modulate unique and difficult disease targets in diverse therapeutic areas. The company was founded by Mark L. Peterson, and the CEO is Helmut Thomas. | Health Technology |
- Stock Market
- Insiders
- Helmut Thomas